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Edited by Noboru MizushimaAbstract The tumor suppressor ARF is one of the most impor-
tant oncogenic stress sensors in mammalian cells. Its eﬀect is ex-
erted through the interaction with diﬀerent cellular partners,
often resulting in their functional inactivation. This review fo-
cuses on the role played by the proteasome in ARF regulation
of protein turnover and the function of most of its interacting
partners. Speciﬁc proteasome components appear to be involved
in the regulation of ARF turnover, bringing to light a complex
network of interactions between ARF and the proteasome.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Since the discovery of MDM2 as its ﬁrst molecular partner,
ARF function has been linked to tumor suppression. Both the
human (p14ARF) and mouse (p19ARF) proteins function as
important sensors of hyperproliferative stimuli acting to re-
strict cell proliferation through both p53-dependent and inde-
pendent pathways [1].
Normal cells contain low levels of ARF but the expression of
a variety of proliferation-promoting proteins, including Myc,
E2F, E1A, oncogenic Ras and v-Abl, upregulate ARF as part
of a checkpoint response conveying on the well known p53-
MDM2 pathway [2]. The discovery of multiple ARF interac-
tors and the observation that, aside oncogenic stimuli, also
viral, genotoxic, hypoxic and oxidative stresses activate an
ARF-dependent response, suggest that ARF could exert a
wider role to protect the cell [3–6].
It is becoming clear that the ARF response is quite complex
and is likely accomplished by the interaction with a multitude
of diﬀerent cellular partners that in part explain the p53-inde-
pendent activities of ARF. However, ARF partners are very
heterogenous, making diﬃcult and confusing the formulation
of a unique model that could depict the ARF role in the cell.
Furthermore, ARF appears to exert diﬀerent and sometimes
apparently contrasting eﬀects on its partners: functional inac-
tivation, that can be achieved by increase of degradation
(accomplished by both ubiquitin-dependent and independent*Corresponding author. Fax: +39 081 79233.
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doi:10.1016/j.febslet.2008.09.026mechanisms) and/or subcellular relocalization, and in some
cases, stabilization.
On the other hand, regulation of ARF intracellular levels it-
self is still not yet completely clear. While ARF activation fol-
lowing stress insults – mostly occurring through transcriptional
activation – has been the focus of intensive studies, the mecha-
nisms regulating ARF protein turnover have been neglected for
long time. Given its strong ability to block both growth and
proliferation, cells must develop mechanisms that promptly re-
duce ARF protein levels when its activity is no more required.
However, the mechanisms regulating ARF turnover are still
controversial and appear not to be unique.
The discovery that p14ARF can directly interact with regula-
tive components of the proteasomemulti-protein complex, such
as TBP-1/PMSC3 of the 19S subunit [7,8] and REG-c of the 11S
lid [9] oﬀers a new key to interpret the mechanisms through
which ARF is regulated and regulates cell growth and prolifera-
tion.2. ARF intracellular protein levels are controlled by the
proteasome
The proteasome is the chief site of protein destruction in
eukaryotic cells. It is made by the dynamic, ATP-dependent
association of the 20S catalytic proteasome (made by four
stacked heptameric rings) with the regulatory 19S subunit that
sits as a ‘‘collar’’ on one or both ends of the 20S proteasome –
although ‘‘free’’ 20S as well as 19S caps can be found in the cell
[10,11]. 19S regulatory subunit is composed of a ‘‘base’’ (with
ATPase activity) that binds directly to the 20S core particle,
and a ‘‘lid’’ that usually contacts substrates that have to be de-
graded. Protein proteolysis requires recognition of the sub-
strate, its unfolding and translocation into the cavity of the
20S proteasome. Ubiquitinated proteins are sent to the 20S
catalytic barrel-shaped proteasome core by ubiquitin-depen-
dent binding to the 19S particles whose function is to open
the barrel and allow protein entry [11].
On the other hand, non ubiquitinated proteins can also be
degraded by the 20S proteasome, as well as by the 26S protea-
some itself [12–14]. Nonetheless, the mechanism by which pro-
teasomes recognize proteins in the absence of ubiquitination is
not understood and appear to mainly regard small, unstruc-
tured proteins that can gain direct access to the core protea-
some without the need for a speciﬁc interaction mechanism.
Activation of the proteasome can also be achieved by bind-
ing of the 11S regulator (also known as REG or PA28) that
triggers the ‘‘opening of the gate’’. The REG/11S particle
can be found, as the 19S proteasome, independent orblished by Elsevier B.V. All rights reserved.
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ticipate to its activation in an ATP-independent fashion. The
REG family of activators has three members: REG-a and
REG-b subunits, usually involved in the MHC class I antigen
presentation, and REG-c primarily residing in the nucleus
[15,16]. The REG-c function is still largely elusive although
knock out mice suggest a role in the regulation of mitosis
and apoptosis [17–19].
The ﬁrst evidence of a link between ARF and the protea-
some is the observation that both human and mouse ARF
accumulate following treatment with proteasome inhibitors
suggesting that ARF degradation depends, at least in part,
by the proteasome [7,20,21].
For the vast majority of proteins, conjugation of ubiquitin
to internal lysines is the initial event in their degradation by
the ubiquitin–proteasome system. However, the human
p14ARF protein is lysine-less and the murine p19ARF has a
single lysine residue not required for proteasome degradation
[7,20,21]. The same authors observed that ARF can be sub-
jected to N-terminal ubiquitination – a process described in
engineered lysine-less mutants of certain viral and cellular pro-
teins – and that this process appears independent from p53 and
MDM2 [8]. However, others do not report ubiquitination of
the protein but claim the importance of MDM2 in ARF pro-
teasome degradation [21]. On the other hand, according to its
natively unstructured nature, p14ARF can be in vitro de-
graded by the 20S proteasome, in the absence of ubiquitina-
tion, but the mechanisms governing its delivery into the
proteasome still remain to be clariﬁed [8]. Interestingly, a very
recent report describes a direct involvement of the REG-c pro-
teasome in a ubiquitin-independent regulation of the ARF
turnover [22]. The demonstration that REG-c governs the
turnover of ARF and of other important cell-cycle regulators
like p21Cip/WAF1 and p16INK4a, suggests that the REG-c
pathway represents a new important mechanism to control
protein turnover [22]. These observations, in agreement with
previous data suggesting a role for REG-c only in the degrada-
tion of short peptides, lead to the hypothesis that this pathway
could be specialized for the proteasomal degradation of small
unstructured proteins since p19ARF, p21, and p16 are all
unstructured when not associated with speciﬁc binding part-
ners (such as cyclins and Cdks, for p21 and p16, and nucleo-
phosmin in the case of p19ARF). However, the fact that
REG-c is involved in the ubiquitin-independent proteolysis
of the oncogenic protein steroid receptor coactivator-3
(SRC-3) challenges the idea that REG-c is implicated only in
the degradation of substrates with disordered elements
[23,24]. An interesting possibility is that the feature of proteins
targeted to the REG-c pathway is the lack of ubiquitination,
usually due to the absence of lysine residues. Both p16 and hu-
man p14ARF are naturally lysine-less proteins [25,26] and p21
and SRC-3 can be degraded in the absence of ubiquitination
[22,27]. Interestingly, viral proteins constitute a substantial
subset of naturally lysine-less proteins. This raises the hypoth-
esis that the REG-c pathway might play a role in the control of
viral pathogenesis. This is particularly interesting, given that
ARF activation has been linked to viral response [5].
In this scenario, it is particularly intriguing our observation
that one of the ATPAses, component of the 19S proteasome,
TBP-1/PSMC3, interacts with p14ARF but, unexpectedly, in-
stead of bringing it to degradation, it is involved in its stabil-
ization [7,8]. As a component of the 19S base of theproteasome, TBP-1/PSMC3 is supposed to be involved in the
recognition of ubiquitinated substrates, their unfolding and
presentation to the 20S proteasome. In agreement with this
is the observation that TBP-1/PSMC3 binds to the tumor sup-
pressor pVHL (Von Hippel Lindau) and contributes to its E3-
ubiquitin ligase function toward the Hif1-a factor [28], highly
overexpressed in cancer cells [29]. Of note, ARF also inhibits
Hif1-a with a yet unknown mechanism raising the possibility
that both ARF and TBP-1/PSMC3 convey on the disabling
of the cellular resistance to hypoxia [4].
Thus, TBP-1/PSMC3 appears to serve a role in the control
of cell proliferation both through the increase of degradation
of an oncogene and the stabilization of an oncosuppressor.
However, it has to be noted that TBP-1/PSMC3, as well as
the other family members of ATPAses that are part of the
19S proteasome, appears to be a multifunctional protein, being
also involved in cellular processes other than proteolysis [30–
32] such as the control of transcription [33,34]. Other interest-
ing evidences support the potential role of TBP-1/PSMC-3 as a
tumor suppressor: its expression was found to be upregulated
following inhibition of the oncogenic phenotype of erb-B
transformed cells; its overexpression diminished cell prolifera-
tion [35], reduced the ability to form colonies in colony forma-
tion eﬃciency (C.F.E.) [8] and strongly inhibited the
transforming eﬃciency in athymic mice [35].
But how TBP-1/PSMC3 acts on ARF?
Strikingly, TBP-1/PSMC3 counteracts, in vitro, the degrada-
tion of ARF by the 20S proteasome, in the absence of an
assembled 19S regulative cap [8]. Given that 19S proteasome
subunits possess chaperone-like activities, (residing in the
ATPase module), we hypothized that, upon binding, TBP-1/
PSMC3 could, in part, cause a folding of ARF, rendering it
a poor substrate for proteasome destruction. Accordingly, a
TBP-1/PSMC3 point mutant in the ATPAse domain is
strongly impaired in its capacity to stabilize ARF, strongly
suggesting that a chaperone activity is required for the ob-
served eﬀect (Pollice et al., unpublished results). This is partic-
ularly interesting since, among the plethora of ARF interacting
partners, only TBP-1 and NPM/B23 are involved in ARF sta-
bilization. However, while B23 prevents ARF degradation
retaining it into the nucleolus in an inactive form [49], TBP-
1/PSMC3 is clearly excluded from the nucleolus and binds to
ARF mainly in the nuclear compartment [7,8]. This interaction
causes an accumulation of ARF that results in the activation
of its biochemical functions, at least in the p53/HDM2 path-
way [7,8].
Altogether these observations represent new clues in the
comprehension of the mechanisms of regulation of ARF intra-
cellular levels. Whether ARF could bind to the entire 19S or
11S/REG-c particle as well as to the 20S proteasome in vivo
has still to be explored. However, it is envisionable that alter-
native binding of ARF to diﬀerent proteasome subunits, REG-
c or TBP1/PSMC3, could mediate either its stabilization or its
degradation (Fig. 1). It would be of great interest to investigate
on the hypothesis of a direct competition between REG-c and
TBP-1/PSMC3 for the binding to ARF and to explore the
stimuli and molecular pathways involved.
The remaining open question now would be: which kind of
signals dictates the ARF fate (either stabilization or degrada-
tion) and how these are transduced through the proteasome?
The signals that regulate either expression or association of
the various proteasome components are not yet clear and ap-
Fig. 1. A model for the regulation of ARF turnover. ARF can be
degraded by the proteasome through ubiquitin-independent (by the
20S or 20S/REG-c complex) or dependent (by 26S complex) mecha-
nisms. Binding to the 19S subunit PSMC3/TBP-1 protects ARF both
in vitro and in cells (see text for detail).
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like core 20S proteasomes, are distributed in nuclear and cyto-
solic fraction. However, some signiﬁcant diﬀerences were ob-
served in the ratio of diﬀerent subunits of 19S complexes in
diﬀerent subcellular locations, suggesting that the proteasome
species can vary in the precise subunit composition [36]. Pro-
teasome species thus appear as highly dynamic structures
achieved through the recruitment and exchange of diﬀerentFig. 2. A schematic view of the ‘‘ARF harem’’ described in this review. Oran
that are induced to proteasome and ubiquitin-dependent degradation by AR
independent degradation by ARF. Green is for partners whose activity or stab
ARF protein turnover. A second black circle indicate nucleolar sequestratioregulatory caps [37]. The REG-a and b subunits appear to
be mainly localized in the cytoplasm, enriched in the endoplas-
mic reticulum, while REG-c is predominantly nuclear in interf-
ase cells, being localized on chromosomes during telophase
[19]. c-Interferon treatment appears to induce an increase in
the levels of REG-a and b subunits, but not a change in their
subcellular distribution. Phosphorylation of some proteasome
subunits (either components of the 20S and of the 19S) also ap-
pears to play a role in the association between 19S and 20S
proteasomes [38]. Furthermore, growth factors appear to reg-
ulate the intracellular levels of at least some 19S proteasome
subunits, although the precise mechanisms and pathways in-
volved are not yet clear: while stimulation by heregulin b1 of
breast epithelial cancer cells (MCF7 cells) determines an in-
crease of the S4/Rpt2 ATPase [39] acute insulin stimulation
of U2OS osteasarcoma cell line causes a reduction of TBP-1/
PSMC3 intracellular levels (Pollice et al., unpublished data).3. ARF regulates the protein turnover and function of most of its
interacting partners
During the last years many eﬀorts have been attempted in
search of ARF partners that could partly explain the p53-
Mdm2 ARF independent functions. In addition to its ﬁrst
‘‘spouse’’ MDM2 [40–43], the ARF interactors ‘‘harem’’ con-
sists of something like 30 diﬀerent proteins involved in various
cellular activities (Fig. 2): proteins involved in transcriptional
control, such as E2Fs [44], DP1 [45], c-Myc [46], p63 [47],
Hif1a [4], Foxm1b [48], nucleolar proteins such as nucleolin/
C23 and nucleophosmin (NPM/B23) [49], viral proteins such
as HIV-1Tat [50], proteins involved in copper metabolism like
COMMD1 [51], proteins involved in chromosomal stability
and/or chromatin structure such as Topoisomerase I [3,52],
Tip60 [3,52], and WRN helicase [53], ubiquitin ligases like
Ubc9 [54,55] (the E2 ligase required for sumoylation),
MDM2 and ARF-BP1/Mule, (E3-ubiquitin ligases) [57].ge is for partners whose activity is blocked by ARF. Red is for partners
F. Pink is for partners that are induced to proteasome and ubiquitin-
ility are positively regulated by ARF. Blue is for partners that regulate
n.
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activity of its partners is still unclear, the functional conse-
quence is, quite invariably, inactivation [1].
For some targets, ARF interaction causes alteration of sta-
bility. For example, B23/NPM and E2F become degraded by
the proteasome in an ubiquitin-dependent manner, while the
CtBP2 antiapoptotic transcriptional co-repressor and HIV-1
Tat become degraded by the proteasome in a ubiquitin-inde-
pendent manner [56]. Other targets changes their localization
like E2Fs, c-Myc, Foxm1B, MDM2, ATR, DP-1, Hif1a upon
ARF expression. Only few others, like Tip60, Topo I and
COMMD1 become activated or stabilized. Finally, most of
the partners become sumoylated although a precise function
to this modiﬁcation has not yet been assigned [55,57–59].
Particularly interesting is the inhibitory eﬀect that ARF ex-
erts on oncogenes such as members of the E2F family, required
both for cell-cycle progression and to mediate ARF oncogenic
activation, suggesting a potential role of these interactions as
being part of a negative feedback loop. In a series of reports
ARF was shown to interact with E2F1, and this interaction
prevented the formation of active E2F1 transcritional com-
plexes, inhibited E2F1 transactivation potential, and promoted
the proteasome-dependent degradation of E2F1, 2 and 3
[44,60–62]. The regulation of the ARF-dependent E2F1 turn-
over by the proteasome appears to involve E2F1 ubiquitina-
tion [62], although the genetic context in which this process
occur is not yet completely clear.
In line with a role of ARF in promoting ubiquitin-depen-
dent degradation of its partners is the observation that
NPM/B23, an abundant nucleo/nucleolar multifunctional
protein involved in ribosome biogenesis [63,64], is a molecu-
lar target of ARF. The vast majority of ARF appears local-
ized in nucleoli, tightly associated with NPM/B23.
Interestingly, the ARF-B23/NPM interaction seems critical
in the regulation of both proteins [49,65]. Under normal con-
ditions, B23 appears to retain ARF in the nucleolus, retard-
ing its turnover. Indeed, the stability and nucleolar
localization of ARF is markedly reduced in cells lacking
NPM and leukemia-associated NPM mutants are unable to
stabilize ARF [66]. However, ARF hyper-expression induces
B23 proteasomal degradation by increasing its ubiquitination
rate and proteasomal degradation bringing to an inhibition of
rRNA processing [64]. These observations lead to the conclu-
sion of the existence of a regulative loop between ARF and
B23, in which degradation and inhibition of both proteins
is ﬁnely and tightly modulated by external stimuli. In such
a situation, ARF serves a dual function to restrain both
growth and proliferation.
Interestingly, ARF appears to mediate also ubiquitin-inde-
pendent degradation like that of the antiapoptotic transcrip-
tional co-repressor C-terminal binding protein 2 (CtBP2).
CtBP2 is degraded by the proteasome after UV exposure
leading to apoptosis in colon cancer cells [67]. It has been
shown that UV induced CtBP2 degradation by the protea-
some is dependent on ARF intracellular protein levels. More-
over, human ARF hyper-expression without UV stimulation,
resulted in proteasome mediated degradation of CtBP2, not
accompanied by an appreciable increase in CtBP2 ubiquitina-
tion [56] although CtBP2 is ubiquitinated in the cells used.
Still open is the possibility that the experimental system used
was not enough sensitive to detect changes in the levels of
ubiquitination.p14ARF has also been shown to mediate the proteasome-
dependent, ubiquitin-independent degradation of the HIV1-
Tat protein [50]. Interestingly, MDM2 has been shown to
ubiquitinate HIV1-Tat, although, in this case, ubiquitination
determines an increase of the Tat-mediated transactivation
properties [68]. This lead to the speculation that ARF could
act on HIV-1Tat in two ways: directly mediating its degrada-
tion and inhibiting the MDM2 activity versus Tat, thus block-
ing viral transcription. This hypothesis would intriguingly ﬁt
with the ARF role in viral defense [5].
As mentioned above, in some cases, ARF is able to stabilize
its partners from proteasomal degradation. In a quite recent
study, it has been described the ARFs ability to induce a
non-classical poly-ubiquitination of a new interacting partner,
the COMMD1 factor [51], a multifunctional protein involved
in copper metabolism and apoptosis. While in normal condi-
tions COMMD1 is degraded by the proteasome, ARF coex-
pression leads to a stabilization of the protein through its
poly-ubiquitination on K63 lysine of the ubiquitin peptide.
K63 is distinct from the classical, K48-linked ubiquitination,
usually involved in protein degradation. Interestingly, most
neurodegenerative diseases like Parkinson disease, are marked
by the presence of ubiquitin-positive protein inclusions that es-
cape proteasomal degradation despite being enriched with
ubiquitin: it has been observed that K63 poly-ubiquitination
plays a role in this stabilization [69].
Altogether, although these observations do not explain the
molecular mechanisms of ARF eﬀects on many of its targets,
they reinforce the idea that the ARF antioncogenic activity
couldbe partly exerted through the cellular degradationmachin-
ery.
In this sense, ARF interaction with the proteasome could
serve dual roles: on one side it is necessary to regulate ARF
protein turnover, while, on the other side, it could play a role
in bringing ARF interacting partners in contact with the ubiq-
uitin/proteasome machinery.
For example, the interaction of ARF with TBP-1/PSMC3 is
necessary to stabilize ARF, but we could speculate that, at the
same time, it could mediate the drag of its targets into the pro-
teasome cavity. The reported observations that both TBP-1/
PSMC3 and ARF exert a negative eﬀect on Hif1a [4,28], seem
to support the idea that a synergy of action between ARF and
the proteasome could occur.
In conclusion, the ‘‘promiscuity’’ of ARF interactions could
hide a very complex regulative network whose players are just
coming to light. Unraveling the mechanisms that mediate the
modulation of intracellular levels of the diﬀerent regulative
proteasome subunits would be crucial for the comprehension
of the ARF protein turnover and function.
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